Home > Insider Trading > Filing (0001209191-21-037402)

Filing Details

Accession Number:: 0001209191-21-037402
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-02 18:40:34
Reporting Period:: 2021-02-01

Accepted Time:: 2021-06-02 18:40:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1845337	Day One Biopharmaceuticals Inc.	DAWN	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1708269	Atlas Venture Fund Xi, L.p.	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No
1759241	Atlas Venture Opportunity Fund I, L.p.	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No
1780065	Atlas Venture Associates Opportunity I, L.p.	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No
1780066	Atlas Venture Associates Opportunity I, Llc	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No
1780067	Atlas Venture Associates Xi, Llc	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No
1780068	Atlas Venture Associates Xi, L.p.	300 Technology Square, 8Th Floor Cambridge MA 02139	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-06-01	7,761,380	$0.00	7,761,380	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-06-01	741,396	$0.00	741,396	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-06-01	250,000	$16.00	250,000	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2021-06-01	250,000	$16.00	250,000	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Acquisiton	2021-02-01	741,396	$0.00	741,396	$0.00
Common Stock	Series A Preferred Stock	Disposition	2021-06-01	7,761,380	$0.00	7,761,380	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-06-01	741,396	$0.00	741,396	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
741,396	No	4	P	Indirect
0	No	4	C	Indirect
0	No	4	C	Indirect

Footnotes

The shares of the Issuer's Series A Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-255754) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.
The shares are held directly by Atlas Venture Fund XI, L.P. ("Fund XI"). The general partner of Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Fund XI, except to the extent of its pecuniary interest therein, if any.
The shares of the Issuer's Series B Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.
On June 1, 2021, Fund XI purchased 250,000 shares of common stock of the Issuer at a purchase price of $16.00 per share pursuant to an underwritten public offering.
On June 1, 2021, Atlas Venture Opportunity Fund I purchased 250,000 shares of common stock of the Issuer at a purchase price of $16.00 per share pursuant to an underwritten public offering.
The Reporting Person is reporting the purchase of these securities pursuant to Rule 16a-2(a) of the Securities Exchange Act of 1934, as amended. Each share of Series B Preferred Stock automatically converted into one share of Common Stock at the close of the Issuer's IPO and has no expiration date.